Thiotepa intrathecal injections for myelomatous central nervous system involvement

Br J Haematol. 2021 Apr;193(2):e9-e12. doi: 10.1111/bjh.17343. Epub 2021 Mar 9.

Authors

Alexis Claudel¹, Alexis Talbot¹, Stéphanie Harel¹, Bruno Royer¹, Lombion Naelle¹, Anne-Marie Zagdanski², Isabelle Madelaine³, Pierre Lemaire⁴, Bertrand Arnulf¹

Affiliations

¹ Immuno-Hematology Department, Saint-Louis Hospital (APHP), University of Paris Diderot-Paris VII (Sorbonne Paris Cité), Paris, France.
² Department of Radiology, Saint-Louis Hospital (AP-HP), University of Paris Diderot-Paris VII (Sorbonne Paris Cité), Paris, France.
³ Pharmacy Department, Saint-Louis Hospital (APHP), University of Paris Diderot-Paris VII (Sorbonne Paris Cité), Paris, France.
⁴ Hematology Laboratory, Saint-Louis Hospital (APHP), University of Paris Diderot-Paris VII (Sorbonne Paris Cité), Paris, France.

PMID: 33686665
DOI: 10.1111/bjh.17343

No abstract available

Keywords: central nervous system; extramedullary disease; intrathecal injections; multiple myeloma; thiotepa.

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents, Alkylating / administration & dosage*
Antineoplastic Agents, Alkylating / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System / drug effects*
Central Nervous System / pathology
Female
Humans
Incidence
Injections, Spinal
Male
Meningeal Neoplasms / drug therapy
Meningeal Neoplasms / pathology
Methylprednisolone / administration & dosage
Methylprednisolone / therapeutic use
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy*
Multiple Myeloma / epidemiology
Neuroprotective Agents / administration & dosage
Neuroprotective Agents / therapeutic use
Plasmacytoma / cerebrospinal fluid
Plasmacytoma / diagnosis
Plasmacytoma / drug therapy*
Safety
Thiotepa / administration & dosage*
Thiotepa / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Neuroprotective Agents
Thiotepa
Methylprednisolone